This page shows the latest Iptacopan news and features for those working in and with pharma, biotech and healthcare.
Novartis has announced detailed results from its pivotal phase 3 APPLY-PNH trial, in which its oral monotherapy iptacopan demonstrated superiority over anti-C5 therapy in adult patients with paroxysmal nocturnal ... Results from the study, which the
Novartis has announced positive topline results from a phase 3 trial in which its investigational oral monotherapy iptacopan demonstrated 'clinically meaningful superiority' over anti-C5 therapies (eculizumab or ravulizumab) in adults ... Iptacopan acts
New treatment options are needed, and these positive results further strengthen the profile of iptacopan as a promising oral monotherapy. ... At the highest dose of 200mg twice daily, a 23% reduction in proteinuria was predicted with iptacopan treatment
Swiss pharma company Novartis has received a breakthrough therapy designation (BTD) for its experimental medication iptacopan for the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). ... Iptacopan is the most advanced asset in our
More from news
Approximately 4 fully matching, plus 0 partially matching documents found.
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...